However, the high levels of three (HLA-DR, FGL-1, and galectin-3) of the putative LAG-3 ligands10 in cancer cells, confirming the involvement of these molecules in blunting antitumor immunosurveillance11, points to the expression of HLA-DR, FGL-1, and/or galectin-3 as potential predictive factor of sensitivity to LAG3 blockade therapy. This evidence concerns the gene LGALS3 and cancer.